Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

Author(s):
Al-Laith, M.; Jasenecova, M.; Abraham, S.; Bosworth, A.; Bruce, I.N.; Buckley, C.D.; Ciurtin, C.; D'Agostino, M.A.; Emery, P.; Gaston, H.; Isaacs, J.D.; Filer, A.; Fisher, B.A.; Huizinga, T.W.J. (0000-0001-7033-7520); Ho, P.; Jacklin, C.; Lempp, H.; McInnes, I.B.; Pratt, A.G.; Ostor, A.; Raza, K.; Taylor, P.C.; Schaardenburg, D. van; Shivapatham, D.; Wright, A.J.; Vasconcelos, J.C.; Kelly, J.; Murphy, C.; Prevost, A.T.; Cope, A.P.
Published
2019
Publication type
Article / Letter to editor
Rheumatoid arthritisAt riskPre-clinical phaseInterventionAbataceptDouble-blindAntibodies to citrullinated protein antigensAutoantibodiesPlacebo-controlledRandomised
Date issued
2019-07-15
Language
English
Is part of
Trials
hdl
1887/119989
doi
10.1186/s13063-019-3403-7